提醒

Vericel Corporation (VCEL)

NasdaqGM: VCEL · 即時價格 · USD

43.59

-0.61 (-1.38%)

收盤時： Aug 18, 2026, 9:52 AM

-1.38% (1D)

買價	n/a
市值	2.23B
營收 (ttm)	306.3M
淨利（ttm）	24.22M
貝塔	1.07
EPS (ttm)	0.48
本益比（ttm）	90.81
正向 PE	51.52
P/B (ttm)	6.03
P/S (ttm)	7.29
Earnings Date	Nov 5, 2026

賣價	n/a
成交量	250,743
20 日平均成交量	584,975
打開	43.75
上一頁關閉	44.20
日間範圍	43.41 - 44.31
52 週範圍	28.95 - 49.32
分析師	Strong Buy
目標價	59 (35.35%)
股利	n/a
Ex-股利日期	n/a

關於VCEL

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-...

[閱讀更多]

工業 Biotechnology

部門 Healthcare

IPO 日期 Feb 4, 1997

員工 398

證券交易所 NasdaqGM

股票代號 VCEL

網站 https://www.vcel.com

完整的公司簡介

財務表現

Vericel 在 2025 年的營收為 276.26M，較前一年的 237.22M 增加 16.45%。淨利為 16.52M，較前期增加 59.41%。

財務報表

分析師預測

根據7 分析師評等，VCEL股票的平均評等為「Strong Buy」。 12個月股價預測為59，與最新價格相比為上漲空間的35.35%。

股票預測

獲利驚喜

Vericel 已於 Jul 30, 2026 公布季度財報：

營收的 $77.46M 錯過估計 $0, 與 22.48% YoY 成長.

EPS 的 0.04 超出估計 0.07, 與 500.00% YoY 成長.

下次財報發布

Vericel Corporation 定於發布財報 Nov 5, 2026, 開市前。
分析師預估營收 ... 升級

新聞動態

4 天前 · MarketBeat

MediWound Q2 Earnings Call Highlights

MediWound (NASDAQ:MDWD) reported second-quarter 2026 revenue of $3.1 million, down from $5.7 million a year earlier, as the company continued investing in its Phase III EscharEx chronic-wound program ...

2 週前 · IPO-Edge.com

Next GLP-1 Billion-Dollar Market: Fireside Chat with Conexeu Sciences CEO Miles Harrison

IPO Edge hosted a fireside chat with Conexeu Sciences Inc. (Nasdaq: CNXU) President and Chief Executive Officer Miles Harrison, moderated by IPO Edge Editor-in-Chief John Jannarone and Editor-at-Large...

2 週前 · MarketBeat

Vericel Q2 Earnings Call Highlights

Vericel (NASDAQ:VCEL) reported record second-quarter revenue and raised its full-year outlook, citing continued growth in its MACI cartilage repair franchise and Burn Care business, along with improve...

2 週前 · Zacks

Vericel Corporation (VCEL) Beats Q2 Earnings and Revenue Estimates

Vericel (VCEL) delivered earnings and revenue surprises of +200.00% and +7.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

1 月前 · Motley Fool

Vericel Stock Is Up 10%. Here's What This $402,000 Insider Sale Really Suggests

Focused on regenerative therapies for sports medicine and burn care, this biopharma firm reported a notable insider sale in June.

第 1 頁，共 2 頁

Vericel Corporation (VCEL)